Efficacy of Kava Extract for Treating Anxiety: Systematic Review and Meta-Analysis
- 1 February 2000
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 20 (1) , 84-89
- https://doi.org/10.1097/00004714-200002000-00014
Abstract
Synthetic anxiolytic drugs are effective for treating anxiety, but they are burdened with adverse effects. Constraints on resources and time often render therapies such as psychologic interventions impracticable. Thus, an effective oral medication with few adverse effects would be a welcome addition to the therapeutic repertoire. This systematic review and meta-analysis was aimed at assessing the evidence for or against the efficacy of kava extract as a symptomatic treatment for anxiety. Systematic literature searches were performed in the computerized databases MEDLINE, EMBASE, BIOSIS, AMED, CISCOM, and the Cochrane Library (all from their respective inception to June 1998). The search terms used were kava, kawa, kavain, Piper methysticum, and Rauschpfeffer (German term for Piper methysticum). Experts on the subject were contacted to provide further information. There were no restrictions regarding the language of publication. Double-blind, randomized, placebo-controlled trials of oral kava extract for the treatment of anxiety were included. All publications were blinded before assessment by a person not involved in the study. Data were extracted in a standardized, predefined fashion independently by the two reviewers. The methodologic quality of all trials was assessed. Superiority of kava extract over placebo was suggested by all seven reviewed trials. The meta-analysis of three trials suggests a significant difference in the reduction of the total score on the Hamilton Rating Scale for Anxiety in favor of kava extract (weighted mean difference, 9.69; 95% confidence interval, 3.54-15.83). These data imply that kava extract is superior to placebo as a symptomatic treatment for anxiety. Therefore, kava extract is an herbal treatment option for anxiety that is worthy of consideration.Keywords
This publication has 26 references indexed in Scilit:
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996
- Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trialsJAMA, 1995
- Der psychoaktive Spezialextrakt WS 1490 aus dem Wurzelstock von Piper methysticum (Kava-Kava) – ein ReportComplementary Medicine Research, 1994
- Kava Pyrones and Resin: Studies on GABAA, GABAB and Benzodiazepine Binding Sites in Rodent BrainBasic & Clinical Pharmacology & Toxicology, 1992
- Publication bias in clinical researchThe Lancet, 1991
- Generalized anxiety disorderInternational Review of Psychiatry, 1991
- The Efficacy of Cavain in Patients Suffering from AnxietyPharmacopsychiatry, 1989
- EEG‐Brain mapping, psychometric and psychophysiological studies on central effects of kavain ‐ a kava plant derivativeHuman Psychopharmacology: Clinical and Experimental, 1989
- Benzodiazepines and Dependence: A College StatementPsychiatric Bulletin, 1988
- Psychoactive Substances of the South Seas: Betel, Kava and PituriAustralian & New Zealand Journal of Psychiatry, 1985